Payment overview · 2025
General Payments
$122.90
6 reported records · 6 companies
Healthcare provider profile · identity verified
Julius Anthony Debroeck, MD
Allopathic & Osteopathic Physicians|Family Medicine · CYPRESS, TX · NPI 1023180429
Verified facts
What the public records show
CMS Open Payments records show Julius Anthony Debroeck, MD received $122.90 in general payments during 2025 across 6 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.76 | 25.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.64 | 21.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.93 | 16.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.14 | 13.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.87 | 12.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.56 | 11.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $122.90 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 170 |
| Atorvastatin Calcium | Atorvastatin Calcium | 476 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 342 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 328 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 295 | 89 |
| Meloxicam | Meloxicam | 237 | 77 |
| Losartan Potassium | Losartan Potassium | 184 | 53 |
| Lisinopril | Lisinopril | 171 | 59 |
| Montelukast Sodium | Montelukast Sodium | 171 | 60 |
| Clonazepam | Clonazepam | 170 | 29 |
| Gabapentin | Gabapentin | 169 | 49 |
| Metformin Hcl | Metformin Hcl | 160 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 55 |
| Omeprazole | Omeprazole | 140 | 40 |
| Metformin Hcl Er | Metformin Hcl | 139 | 43 |
| Tramadol Hcl | Tramadol Hcl | 133 | 32 |
| Alprazolam | Alprazolam | 132 | 22 |
| Trazodone Hcl | Trazodone Hcl | 129 | 35 |
| Simvastatin | Simvastatin | 120 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 39 |
| Allopurinol | Allopurinol | 115 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 29 |
| Ozempic | Semaglutide | 92 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 28 |
| Synthroid | Levothyroxine Sodium | 90 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 30 |
| Sertraline Hcl | Sertraline Hcl | 72 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 23 |
| Furosemide | Furosemide | 70 | 24 |
| Memantine Hcl | Memantine Hcl | 68 | 14 |
| Pregabalin | Pregabalin | 68 | 16 |
| Ondansetron Odt | Ondansetron | 67 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 15 |
| Famotidine | Famotidine | 59 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 16 |
| Potassium Chloride | Potassium Chloride | 57 | 17 |
| Lorazepam | Lorazepam | 56 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 14 |
| Azithromycin | Azithromycin | 53 | 39 |
| Valacyclovir | Valacyclovir Hcl | 53 | 11 |
| Dutasteride | Dutasteride | 52 | 17 |
| Januvia | Sitagliptin Phosphate | 51 | 14 |
| Azelastine Hcl | Azelastine Hcl | 50 | 13 |
| Farxiga | Dapagliflozin Propanediol | 48 | 12 |
| Atenolol | Atenolol | 47 | 14 |
| Buspirone Hcl | Buspirone Hcl | 47 | 17 |
| Glimepiride | Glimepiride | 45 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 16 |
| Eszopiclone | Eszopiclone | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 13 |
| Bupropion Xl | Bupropion Hcl | 42 | 12 |
| Mupirocin | Mupirocin | 42 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 16 |
| Eliquis | Apixaban | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Prednisone | Prednisone | 39 | 17 |
| Fluconazole | Fluconazole | 38 | 18 |
| Celecoxib | Celecoxib | 37 | 15 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 11 |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Methylprednisolone | Methylprednisolone | 32 | 28 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | 12 |
| Valsartan | Valsartan | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 17 |
| Invokana | Canagliflozin | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Cefdinir | Cefdinir | 22 | 18 |
| Glipizide | Glipizide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Focalin Xr | Dexmethylphenidate Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tirosint | Levothyroxine Sodium | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $122.90 · 6 records | Boehringer Ingelheim Pharmaceuticals, Inc. | Cologuard Collection Kit, FARXIGA, INSPIRE, PREVNAR 20, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error